VYNE THERAPEUTICS INC (VYNE) Stock News
NASDAQ:VYNE - Nasdaq - US92941V3087 - Common Stock - Currency: USD
VYNE Latest News, Press Relases and Analysis
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025Expected cash runway into 2H 2026 BRIDGEWATER, N.J., May 08, 2025 ...
VYNE Therapeutics Provides Update on VYN202 Program
BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the U.S. Food...
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
VYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips VYNE Therapeutics (NASDAQ:VYNE) just reported results for the second quarter of...
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025VYN202 Phase 1b psoriasis trial initiated with results anticipated by...
VYNE Therapeutics to Participate in March Investor Conferences
BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial...
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
Once-daily VYN201 gel being evaluated in subjects with nonsegmental vitiligoTop-line data from the 24-week double-blind portion of the trial expected in...
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
Promising results support VYN202’s potential as a novel, once-daily oral treatment for a broad range of immune-mediated disordersConsistent with Phase 1a...
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for...
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood...
VYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024
VYNE stock results show that VYNE Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo, with top-line results expected in mid-2025Phase 1a SAD/MAD trial of VYN202 progressing, with...
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases...
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
VYN202 has been designed to achieve class-leading potency and BD2-selectivity Trial will evaluate safety, tolerability, pharmacokinetics and...
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
Trial will evaluate once-daily VYN201 gel in subjects with either active or stable nonsegmental vitiligo Top-line data from the 24-week double-blind...
VYNE Stock Earnings: VYNE Therapeutics Beats EPS, Misses Revenue for Q1 2024
VYNE stock results show that VYNE Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
Design of Phase 2b trial for VYN201 in nonsegmental vitiligo finalized and on track to begin this quarterPhase 2b trial expected to enroll approximately...
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01,...
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a...
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the hottest news this morning!